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ABSTRACT 
      
BACKGROUND: Craniotomy and transphenoidal microsurgery 
are surgical options for treatment of pituitary adenoma at Korle Bu 
Teaching Hospital(KBTH). Despite major advances and reported 
success rates of transphenoidal resection globally, paucity of local 
data regarding visual outcome of either procedure exists.  We 
evaluated the visual outcome of patient with pituitary adenoma 
following surgery in a tertiary hospital in Ghana. 
 
METHODS: This is a prospective study of 18 of 45 consecutive new 
patients with pituitary adenoma seen from November 2010 to July 
2013 at Korle-Bu Teaching Hospital(KBTH), Accra, Ghana. Sixteen 
(88.9%)  of the 18 had surgery by transphenoidal route and 
2(11.1%) by craniotomy. All patients had macroadenoma (tumour 
size >1cm) and histological confirmation of diagnosis. Pre-operative 
and post-operative visual acuity and its relationship to tumour size 
and duration of symptoms before diagnosis were evaluated. 
RESULTS: Data on 18 patients aged 33-60 years, mean (SD) 
45.9±8.5, was analysed.  Eleven (61.1%) were females.Visual blur, 
15(83.3%), and headache,13(72.2%), were predominant presenting 
complaints.Common neuro-ophthalmic signs included unilateral or 
bilateral optic atrophy, 17(94.4%), Relative Afferent Pupillary 
Defect (RAPD) in 8(44.4%) and impaired colour vision in 32 of 
36(88.9%) eyes. Preoperatively, 8(22.2%) and 13(36.1%) of 36 eyes 
were visually impaired or blind respectively. Postoperatively, 
6(16.7%) eyes were visually impaired and 17(47.2%) eyes blind. 
Blindness was associated with late presentation (p<0.005) and 
larger tumour width (p<0.036).   
CONCLUSIONS: More than a third of eyes of patients with 
pituitary adenoma were blind before and after surgery. Blindness 
was associated with late presentation and larger tumours. 
Transphenoidal surgery may be beneficial following early diagnosis 
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Pituitary adenomas account for 10 to 17% of all 
intracranial tumours (1–4), and remain in many 
cases undiagnosed since they may be asymptomatic 
(4). However, some patients may present with well-
defined clinical syndromes due to hormonal 
hypersecretion, including hyperprolactinemia, 
acromegaly,Cushing’s disease and hyperthyroidism 
or with impaired pituitary function due to 
compression of the gland (4). 
Larger tumours with severe supra- and/or 
parasella extension may cause severe headache, 
visual compromise and oculomotor nerve palsy 
(4,5). Surgery remains the treatment of choice for 
majority of these tumours and the gold standard for 
hormonally inactive adenomas (4). In most of  
these tumours, surgery is required for the relief  of 
visual symptoms and prevention of further visual 
deterioration (5). 
The most widely used surgical approach for 
pituitary adenomas since the 1960s has been the 
transphenoidal route, using the operating 
microscope. It is the preferred approach for most 
cases of pituitary adenomas, due to its low risk of 
complications coupled with good outcome (4–8).  
Microsurgical transphenoidal surgery has 
been the main surgical method employed at Korle 
Bu Teaching Hospital (KBTH) for pituitary 
adenomas since 2002. Craniotomy is performed for 
giant tumours which are inaccessible by the 
transphenoidal approach. There are, however, no 
published data in Ghana on the visual outcome of 
these patients following transphenoidal resection or 
craniotomy. This study sought to determine the 
visual outcome of patients presenting at KBTH 
with pituitary adenoma after surgery and to identify 
the factors which may influence this outcome. 
 
  MATERIALS AND METHODS   
This was a prospective case series involving 18 
consecutive patients diagnosed with pituitary 
adenoma and treated surgically from November 
2010 to July 2013. Patients who received either 
medical or no treatment, as well as those  who did 
not consent to participation were excluded from the 
study.  
Ethical approval was obtained from the Ethical and 
Protocol Review Committee of the University of 
Ghana Medical School. Pre-operatively, all the 18 
patients had clinical (neurological, endocrine and 
ophthalmic) diagnosis of pituitary adenoma with 
confirmation by either computerised tomography 
(CT) or magnetic resonance imaging (MRI).  
Patients had surgery either by transphenoidal 
route or by craniotomy. All patients had 
histological confirmation of their diagnosis. 
Demographic (age, sex, history of symptoms), 
clinical (ophthalmic, endocrine, neurologic) and 
histopathological data were recorded using a 
predesigned questionnaire. 
Ophthalmic evaluation included  visual acuity 
(VA)  tested using Snellen’s chart. For patients who 
were unable to see the letters at the closest test 
distance, the following test sequence was used: 
count fingers (CF) at 1 m, hand movement (HM) at 
1 m, light perception (LP) and no light perception 
(NLP). Best corrected Visual Acuity with 
spectacles (BCVA ) was recorded using WHO  
categories of visual impairment  adapted from the 
International Classification of Diseases (9th 
revision, 1975), visual status was  graded as: 
(a) ‘Blind’ when visual acuity (VA) was <3/60 
(b) ‘Impaired’ when VA was <6/18–3/60   
(c) ‘Normal’ when VA was 6/6–6/18. 
Colour vision was tested using Ishihara 
Colour Vision Charts (38 Plate Edition 1994). 
Anterior segment assessment included slit lamp 
examination (using Topcon ATE-600 2004, Japan), 
pupil reaction to light and Relative Afferent 
Pupillary Defect(RAPD). 
Fundus examination was done using  
biomicroscopy with a + 90D lens, indirect 
ophthalmoscope with +20D/ +28D lenses and  
direct ophthalmoscope through dilated pupils 
(using tropicamide 1%, and or cyclopentolate 1% 
combined with phenylephrine 2.5% eye drops).   
Visual field (C30-2) was assessed using a 
Humphrey visual field analyser (SITA, Carl Zeiss 
Meditec; Dublin CA.USA, 2005) 
Assessment of the size of the tumour was 
done radiologically using Computerised 
Tomography scan (CT scan) Hitachi Eclos -2009 or 
Magnetic resonance imaging (MRI) Hitachi Airis 
elite (OPEN). 
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Endocrine evaluation: This included clinical 
examination of patients by the endocrinologist and 
assessment of anterior pituitary hormones namely 
leutinizing hormone(LH), follicle stimulating 
hormone(FSH), 9am serum cortisol, prolactin 
(PRL), triiodothyronine(free T3), thyroxin(free T4), 
and thyroid stimulating hormone (TSH). 
 
Neurosurgical evaluation: Neurosurgical 
evaluation by the neurosurgeons included history 
and examination of the nervous system: Mental 
state, cranial nerves, coordination, motor and 
sensory examinations.  
Outcome measures: Primary outcome measures 
studied included 
• visual acuity at presentation  
• visual acuity  after surgery  
Secondary outcome measures were  
• size of tumour at presentation. 
• duration of symptoms before presentation.  
Statistical data analysis: Data was captured using 
Microsoft Access and analysed using Statistical 
Package for Social Scientists(SPSS) Version 16.0. 
Continuous numeric data were summarized as 
Mean and Standard deviation (SD) and categorical 
data as percentages (%). Results were presented as 
frequencies, tables and charts. To prove significant 
outcomes, t-test was used to compare mean levels 
of visual acuity between right and left eyes. Mann-
Whitney Test was used for establishing significant 
association between, duration before presentation 
and, visual acuity, and tumour size. Chi-squared 
was used to compare proportions, at 0.05 
significant levels.  Logistic regression analysis 
was used to establish significant association 
between visual acuity and tumour type and size. 
 The association between categorical variables was 
determined using Chi-square test while 
comparison of mean values was performed using 
the one-way analysis of variance (ANOVA) test 





Forty-five consecutive patients were diagnosed 
with pituitary adenoma during the study period, but 
data on 18 patients who had surgical treatment was 
analysed.  The ages of the 18 ranged from 33-60 
years with mean(SD) = 45.9±8.5. Eleven (61.1%) 
were females and 7(38.9%) males. Neuroimaging 
diagnosis was confirmed by CT scan in 15(83.3%) 
of the cases and MRI in 3(16.7%) of them.  
All 18 patients had pituitary macroadenoma 
(tumour size>1cm), confirmed  by neuroimaging. 
Out of the 18 patients who had surgery, 16(88.9%) 
were by transphenoidal route and 2(11.1%) by 
craniotomy.  
 
Duration of symptoms before presentation: The 
duration of symptoms before presentation ranged 
from one day to 96 months with mean (SD) of 
29.9±30.8 months and median of 24 months. Table 
1 shows duration before presentation. 
 
Table 1: Duration of symptoms before presentation 
in 18 patients with pituitary adenoma 
Duration of 








Presenting symptoms and signs: Visual blur (15, 
83.3%) and headache (13,72.2%) were the 
commonest presenting complaints.The commonest 
neuro-ophthalmic signs encountered were RAPD in 
8(44.4%) and unilateral or bilateral optic atrophy in 
17(94.4%) of which 10(55.6%) were bilateral. 
Impaired colour vision occurred in 32(88.9%) of 
the 36 eyes (Table 2). 
Pre- and post-operative Best Corrected Visual 
Acuity (BCVA): 
 Pre-operatively, 21(58.3%) of the 36 eyes were 
visually impaired or blind . Of these,  5(13.8% eyes 
had visual acuity of No Perception of Light (NPL).  
Post-operatively, 23(63.9%) of the 36 eyes were 
visually impaired or blind (Table 3).Post-
operatively, out of 36 eyes, visual acuity improved 
in 9(25%), worsened in 10(27.8%) and remained 
the same in 17(47.2%).  
Considering visual acuity in 32 eyes of the 16 
patients who had transphenoidal resection, vision 
improved in 21(21.9%), worsened in 10(31.2%) 
and remained the same in 15(46.9%) eyes. Eight 
(25%) eyes had pre-operative visual acuities of 
Counting Fingers (CF) to Perception of Light (PL), 
and 4 eyes had visual acuity of NPL (Table 3). Two 
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of 8 eyes with pre-operative visual acuity ranging 
from CF to PL had improved visual acuity after 
surgery. This included one patient with pre-
operative visual acuity of CF in one eye improving 
by 3 Snellen lines to 6/24 and the other with visual 
acuity of Hand Motion (HM) improving by a line to 
Counting fingers(CF).  None of the patients with 
visual acuity of NPL had improvement in visual 















Table 2: Presenting symptoms and signs in 18 patients 
with pituitary adenoma 
 
Symptoms / signs Number (%) 
   Ocular Symptoms 
Visual blur 15(83.3%) 
Ocular pain 4(22.2) 
Diplopia  3(16.7) 
   Ocular signs 
Colour vision impairment (Out 
of 36 eyes) 
32(88.9) 
Optic atrophy 17(94.4) 
RAPD 8(44.4) 
Strabismus 2(11.1) 
Optic disc swelling 1 (5.6) 
Red eye  1 (5.6) 
Non ocular symptoms 
Headache 13(72.2) 
Irregular menses 7(38.9) 
Ammenorrhoea 4(22.2) 
Non Ocular signs 
Galactorrhoea 3(16.7) 
Cranial nerve palsies 0 (0.0) 
 
Table 3:  Preoperative and postoperative monocular visual status of 18 patients with pituitary adenoma. 
 
 
                                Preoperative visual status   
                                          n (%) 
Postoperative visual status  
           n (%) 
Visual status  Right eye  
(n=18) 




Right eye  
(n=18) 




Normal  9(50.0) 6(33.3) 15(41.7) 6(33.3) 7(38.9) 13(36.1) 
Visually impaired 2(11.1) 6(33.3) 8(22.2) 2(11.1) 4(22.2) 6(16.7) 
Blind  7(38.9) 6(33.3) 13(36.1) 10(55.6) 7(38.9) 17(47.2) 
Total  18(100) 18(100) 36(100) 18(100) 18(100) 36(100) 
 
n = number, %= percent 
 
One of the patients who had craniotomy had 
improved vision whilst the other had a drop in 
visual acuity by a Snellen line in one eye (Table 4). 
Time between onset of symptoms and presentation 
at the hospital was longer in the blind patients. 
This was found to be statistically significant 
(p<0.005).Considering the eyes, there was a 
significant association between duration of 
symptoms and blindness in the right eye (p<0.020) 
but not in left eyes (p<0.518). There was a 
significant association between duration of 
presentation for the blind eyes and the normal 
(p<0.004) or visually impaired eyes. (p<0.002). 
 
Visual field status: The commonest pre-operative 
visual field defects encountered in this series were 
unilateral or bitemporal hemianopia 10(55.6%). 
Other visual field defects were superior 
quadrantanopia 2(11.1%), total field loss 2(11.1%) 
and Junctional scotoma 1(5.6%). Visual field test 
was not performed in 3(16.6%) patients because 
the best corrected visual acuity in their better eyes 
ranged from CF to NPL. Post-operatively, visual 
field test results could only be obtained in a few 
patients; hence, the pre-operative and post-
operative results could not be compared. The 
majority of the patients could not do the test due to 
poor vision and financial difficulties. There was no 
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significant association found between age of 
patient and visual status at presentation (p<0.465). 
Tumour size, the widest dimension of tumours, 
was assessed. This ranged from 28.0mm to 
79.4mm, mean (SD) = 39.7 ± 1.3.  
Larger tumour width was associated with 
visual impairment in right eyes (p<0.036).  These 
eyes were more likely to remain visually impaired 
after surgery (p<0.002). In the left eye, however, 
there was no significant association found between 
tumour width and visual impairment before 
(p<0.565) or after (p<0.537) surgery. 
 
 



























Surgery is the  treatment of choice for the majority of 
pituitary adenomas and the “gold standard” for 
hormonally inactive adenomas (1,4). The presence of 
visual deficit is the major indication for surgery by 
either the transcranial or transphenoidal route (7). 
Transphenoidal surgery however is the  most 
common and successful approach due to its low risk of 
complications and applicable to majority of the cases 
(1,4,5,8). In most of  these tumours, it is required for the 
relief of visual symptoms and prevention of further 
visual  deterioration (4,5). 
In this series, visual deterioration was the 
commonest mode of presentation in 83.3% of the 
patients. Visual deterioration was confirmed  on ocular 
examination. The majority (58.3%) of eyes were found 
to be either blind or visually impaired at presentation. 
This finding is higher than that reported in a series  by 
Turner HE et al which showed 39.3% presenting with 
primary symptom of impaired visual acuity (9) but 
corroborates the findings from a study in Kenya (10) 
which reported visual impairment of 87.7%. 
The visual outcome after a trans-sphenoidal 
procedure is usually excellent (4,5,8,10–12). Severe 
visual defects secondary to optic nerve or chiasm 
compression can regress or resolve completely (11). 
Most of the improvement occurs during the first few 
days or weeks following surgery (11). Pre-operatively, 
58.3% of 36 eyes in this study were visually impaired or 
blind. This increased to 63.9% after surgery. This high 
proportion of eyes blind or visually impaired, is not 
surprising considering the fact that a greater percentage 
(94.4%) of patients presented with unilateral or bilateral 
optic atrophy as opposed to 29% in other studies (10) 
with better surgical outcome.  
Serial number of patient  Preoperative 
visual acuity  
 Right eye 
Post-operative 
visual acuity   
Right eye 
Preoperative 
visual acuity  
 Left eye 
Postoperative 
visual acuity 
  Left eye 
1 6/5 6/5 6/36 6/36 
2 6/12 6/12 6/36 6/36 
4 CF NPL 6/36 CF 
7 6/9 6/9 HM CF 
10* 6/36 6/60 NPL NPL 
18 6/18 NPL NPL NPL 
30 6/36 NPL 6/5 NPL 
37 NPL NPL 6/9 6/12 
40 6/5 6/5 6/36 6/18 
41 NPL NPL CF 6/24 
42 6/9 6/6 6/24 6/60 
49 CF HM 6/9 6/6 
56 CF CF PL PL 
62 6/5 NPL 6/5 6/12 
65 6/12 6/6 6/36 6/9 
66* 6/12 6/24 6/12 6/9 
67 HM HM 6/18 6/18 
68 CF CF NPL NPL 
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Close to half of the patients maintained their 
visual acuity, about 20% improved by 1 to 3 Snellen 
lines whereas about a third worsened. This study 
showed lower improvement than in other studies, i.e. 
78% (8), 71% (11), 71. 5% (10) and 76.9% (13). Only 
one patient with pre-operative visual acuity of CF 
improved to 6/24. None of the patients with visual 
acuity of NPL had improvement in visual acuity after 
transphenoidal surgery. This differs from the findings in 
Elgamal et al’s (11) and Ayub et al (5) in which  visual 
acuities of patients with NPL and CF improved after 
surgery. This disparity may be due to the late 
presentation, with over a third of the patients in this 
study presenting after 24 months as opposed to Ayub’s 
(5) study in which the patients whose visual acuities 
improved from NPL had been blind for only 2 to 10 
days. This strengthens the need for early diagnosis and 
surgery in patients with pituitary adenoma.  
Visual field defects are recognized presentations 
of pituitary adenoma (11,14). The typical visual field 
defect pre-operatively is bitemporal hemianopia (15). 
Other visual field defects encountered in other studies 
include superior quadrantanopia, homonymous 
hemianopia, junctional scotoma, total field loss, central 
scotoma, arcuate scotoma and monocular visual 
constriction (16-18).  
The type of visual field defect depends on the 
relation between the optic chiasm and the tumor itself 
(16). Bitemporal hemianopia is due to the anatomical 
compression of the optic chiasm, where the crossing 
nasal fibers of each optic nerve occurs (15). In an  
anatomical post-fixed chiasm (tumour is placed more 
anterior to the chiasm) visual field defects such as 
central scotoma, arcuate scotoma and monocular visual 
constriction can occur. On the contrary, if the tumor 
compresses the optic tracts or there exists a pre-fixed 
chiasm, a homonymous hemianopia may occur (16,17). 
This study demonstrated some of these defects pre-
operatively, with unilateral or bitemporal hemianopia 
being the commonest. Other factors that influence the 
type of visual defects include the size of pituitary 
adenoma (6, 19,20) and tumor volume (21).  
Some studies have demonstrated recovery of 
visual function including visual field defects post-
operatively, with a shorter duration of symptoms, 
younger age and a better preoperative Best Corrected 
Visual Acuity found to be associated with better 
postoperative recovery (7,22). However, others have 
shown little or no recovery of the visual fields (23,24), 
especially in patients with severe optic atrophy,  
suggesting a direct relation between the degree of optic 
atrophy and visual recovery (1,23,25). Given that optic 
atrophy was a major presentation, coupled with 
prolonged duration of symptoms before presentation in 
our patients, post-operative visual field testing (if done) 
could have demonstrated little or no recovery in those 
who had pre-operative visual field defects. 
Unfortunately, post-operative visual field test results 
were obtained in only a few patients. Therefore, the pre-
operative and post-operative results could not be 
compared to corroborate these findings.  
The choice of transphenoidal approach as 
opposed to craniotomy is determined by a number of 
factors including degree of suprasella extension, tumour 
consistency, brain invasion, cerebral edema and 
encasement of the optic apparatus (10). This study 
included only two cases of pituitary adenoma who had 
craniotomy compared with 16 cases who had 
transphenoidal resection. It was, therefore, not possible 
to statistically compare the two surgical options. Kiboi 
et al (10) in their series,where 45% of the patients had 
transphenoidal and 55% transcranial surgeries, found no 
significant difference, statistically, between these two 
approaches. A larger number of cases of craniotomy 
will be needed in this study population to draw any 
meaningful conclusion. 
Visual presentation of pituitary adenoma varies 
depending on the size of the tumour and its proximity to 
optic pathway (11). Large tumour size and closer 
proximity to the optic chiasma in this series may also be 
responsible for poorer postoperative visual outcome. 
Macro adenomas are characterised by a higher 
frequency of neuro-ophthalmological symptoms and 
poorer response to surgical therapy (3).  Whereas micro 
adenomas may have negligible effect, macro adenomas 
can cause severe impairment of visual acuity, colour 
vision and visual field defects by their compressive 
effect on the optic nerves and chiasma (26). 
Optic atrophy was present  in 94% of cases in this 
study as opposed to 13% in Ayub’s (5). It is a sign of 
long standing  chiasmal compression from pituitary 
macro adenomas and is responsible for  poorer 
prognosis following surgery (5). It results from 
secondary retrograde axonal degeneration as the tumour 
grows upwards (5,11). Tumour growth upwards towards 
the optic chiasma is the most frequent extrasella 
extension of pituitary adenoma(3). Macro adenomas 
with  significant suprasella extension have been 
correlated with significantly worse postoperative 
outcomes(3,5,10). 
Tumour consistency, extent of suprasella 
extension and brain invasion are some factors that 
influence the choice of transphenoidal resection as 
opposed to craniotomy. Firmer consistency of tumour 
has been documented  to pose a challenge to adequate 
resection of  suprasella component of large pituitary 
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tumours (5,10). This, however, could not be confirmed 
in our study because the tumour consistency was not 
assessed. 
 Duration of symptoms before presentation 
ranged from one day to 96 months with a  median of 24 
months. This corroborates findings by  Marcus et al 
(12), but differs from Elgamal’s (11). The extensive 
time interval between onset of visual symptoms and 
diagnosis has been noted in many studies (10,11,13). 
Patients who presented blind in this study were more 
likely to present to the hospital later than the visually 
impaired or normal patients (p<0.005). This was similar 
to findings in Kiboi’s series (10). Late presentation, as 
seen in this study, is associated with poorer visual 
outcome following surgery (5,10). Indeed, studies have 
demonstrated that the longer the duration of the 
symptoms of the patients, the poorer the visual outcome 
after surgery (27). 
The degree of visual improvement after surgery 
for pituitary tumours correlates with the size of the 
tumour (28). Largest tumour diameter in this study 
was79.4mm which is larger than that seen in other 
studies (4,13).Wider tumour diameter at presentation in 
this study was associated with preoperative visual 
impairment in the right eye (p<0.036), but not the left 
eye (p<0.565). This significant association between 
tumour size and pre-operative visual acuity corroborates 
findings from Turkey (13). Thotakura et al, 
demonstrated from their series that better visual 
outcome would be achieved in patients with adenomas 
with mean diameter size <3.65 cm (27) while Ho et al 
showed worse visual impairment at presentation and 
after trans-phenoidal adenectomy with tumour size >2 
cm (29). Other studies, however, have found 
improvement in vision post-operatively in larger tumors 
(>3 cm in diameter  and volume >10 cm3) suggesting 
that tumor size does not seem to greatly influence both 
post-operative visual acuity and visual field deficits 
(,30,31). The reason for these varying outcomes is not 
clear, but it may also suggest that visual status pre- and 
post-operatively for pituitary adenoma may be 
influenced by an interplay of multiple factors. The 
significant disparity between tumour size and right and 
left eyes however is not surprising since pituitary 
tumour growth is usually asymmetrical, resulting in 
asymmetric visual field and vision loss (11). 
Invasiveness of tumour is directly associated with 
tumour diameter  and  extrasella extension (3). Garibi et 
al’s study on giant pituitary adenomas found a 
significant association between tumour diameter greater 
than 40mm and extra-sella invasiveness (3). Our study 
did not assess tumour invasiveness. 
In conclusion, more than a third of eyes of 
patients with Pituitary adenoma were blind before and 
after surgery. Blindness was associated with prolonged 
duration of symptoms and larger tumour size. The 
commonest clinical presentations were visual blur and 
optic atrophy. Transphenoidal surgery may be beneficial 
following early diagnosis to avoid irreversible blindness 
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